Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment

T cells in tumors—the so-called tumor infiltrating lymphocytes (TIL) have been studied intensively over the past years. Compelling evidence point to a clinical relevance for high numbers of T cells at the tumor site with CD8 memory T cells as a key denominator for overall survival (OS) in patients with colo-rectal cancer (CRC), and also for others solid cancers. These data goes hand in hand with studies of clonality of TIL showing the T cells among TIL are expanded clonally, and also that tumor specific T cells of CD4 as well as CD8 type are enriched at the tumor site. The tumor microenvironment is hostile to T cell function e.g., due to expression of enzymes that depletes the amino acids tryptophan and arginine, high concentration of tumor secreted lactate, and presence innate cells or regulatory T cells both with suppressive activity. Analyses of the specificity of TILs in melanoma demonstrate that quite few known antigens are in fact recognized by these cultures underscoring patient unique and/or mutated antigens may represent important target for recognition.

[1]  J. Schrenzel,et al.  Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors. , 2007, The Journal of investigative dermatology.

[2]  D. Mason,et al.  A very high level of crossreactivity is an essential feature of the T-cell receptor. , 1998, Immunology today.

[3]  S. H. van der Burg,et al.  Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma , 2009, Clinical Cancer Research.

[4]  T. Schumacher,et al.  Dissection of T-cell antigen specificity in human melanoma. , 2012, Cancer research.

[5]  S. Rosenberg,et al.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.

[6]  H. V. van Boven,et al.  Overall survival and PD‐L1 expression in metastasized malignant melanoma , 2011, Cancer.

[7]  G. Coukos,et al.  Immunotherapy for ovarian cancer: what's next? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Thiers,et al.  Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma , 2009 .

[9]  Y. Cho,et al.  Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. , 2011, Oral oncology.

[10]  S. Dermime,et al.  FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy , 2008, BMC Cancer.

[11]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[12]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[13]  Ton N Schumacher,et al.  Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers , 2009, Nature Methods.

[14]  Hans-Georg Rammensee,et al.  Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. , 2009, Cancer research.

[15]  P. Hwu,et al.  PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. , 2012, Cancer research.

[16]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Jianhong Cao,et al.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.

[18]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[19]  V. Sondak,et al.  Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma , 2012, Journal of immunotherapy.

[20]  J. Zeuthen,et al.  Preferential usage of T-cell receptor alpha beta variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas. , 1994, International journal of cancer.

[21]  H Nagura,et al.  Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. , 2001, Cancer research.

[22]  J. Becker,et al.  Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. , 2009, The Journal of clinical investigation.

[23]  J. Allison,et al.  Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production , 2011, PloS one.

[24]  F. Marincola,et al.  A Tumor-Infiltrating Lymphocyte from a Melanoma Metastasis with Decreased Expression of Melanoma Differentiation Antigens Recognizes MAGE-12 , 2000, The Journal of Immunology.

[25]  J. Becker,et al.  T-cell clonotypes in cancer , 2004, Journal of Translational Medicine.

[26]  T. Jacks,et al.  Expression of tumour-specific antigens underlies cancer immunoediting , 2011, Nature.

[27]  C. Huber,et al.  The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Donia,et al.  Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients , 2012, Journal of Translational Medicine.

[29]  Ekaterina S Jordanova,et al.  High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. , 2007, Cancer research.

[30]  A. Anichini,et al.  Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. , 1995, Cancer research.

[31]  J. Yang,et al.  Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. , 2012, Cancer research.

[32]  C. Aspord,et al.  Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation , 2011, The Journal of experimental medicine.

[33]  Mads Hald Andersen,et al.  Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. , 2003, Seminars in cancer biology.

[34]  P. Romero,et al.  Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1 , 1995, The Journal of experimental medicine.

[35]  W. Clark,et al.  Biomarkers for individual susceptibility to carcinogenic agents: excretion and carcinogenic risk of benzo[a]pyrene metabolites. , 1992, Environmental health perspectives.

[36]  Mads Hald Andersen,et al.  Regulators of apoptosis: suitable targets for immune therapy of cancer , 2005, Nature Reviews Drug Discovery.

[37]  V. Reuter,et al.  CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma , 2007, Proceedings of the National Academy of Sciences.

[38]  R. Scolyer,et al.  Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Choudhuri,et al.  Use of viral promoters in mammalian cell-based bioassays: How reliable? , 2004, Journal of Translational Medicine.

[40]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[41]  J. Castle,et al.  Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.

[42]  D. Schadendorf,et al.  Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model , 2011, Proceedings of the National Academy of Sciences.

[43]  S. Qiu,et al.  Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma , 2009, Clinical Cancer Research.

[44]  S. Rosenberg,et al.  Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes , 2012, Journal of immunotherapy.

[45]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[46]  S. Rosenberg,et al.  Persistence of Multiple Tumor-Specific T-Cell Clones Is Associated with Complete Tumor Regression in a Melanoma Patient Receiving Adoptive Cell Transfer Therapy , 2005, Journal of immunotherapy.

[47]  G. Coukos,et al.  Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. , 2012, Gynecologic oncology.

[48]  C. L. Costantino,et al.  Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. , 2009, Journal of the American College of Surgeons.

[49]  P. Sinha,et al.  Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. , 2012, Seminars in cancer biology.

[50]  K. R. Daghastanli,et al.  HPV16 Tumor Associated Macrophages Suppress Antitumor T Cell Responses , 2009, Clinical Cancer Research.

[51]  E. Mardis,et al.  Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.

[52]  C. Figdor,et al.  Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[53]  D. Parkin,et al.  The global health burden of infection‐associated cancers in the year 2002 , 2006, International journal of cancer.

[54]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[55]  T. Schumacher,et al.  Design and use of conditional MHC class I ligands , 2006, Nature Medicine.

[56]  J. Schelter,et al.  Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[58]  J. Schøller,et al.  Preferential usage of T‐cell receptor αβ variable regions among tumor‐infiltrating lymphocytes in primary human malignant melanomas , 2007 .

[59]  R. Dina,et al.  Immunopathology and Infectious Diseases Correlation of CXCL 12 Expression and FoxP 3 Cell Infiltration with Human Papillomavirus Infection and Clinicopathological Progression of Cervical Cancer , 2010 .

[60]  A. Mackensen,et al.  Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. , 1993, The Journal of clinical investigation.

[61]  J. Becker,et al.  Circulation and homing of melanoma‐reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte‐derived dendritic cells , 2004, International journal of cancer.

[62]  E. Angevin,et al.  Analysis of T‐cell immune response in renal cell carcinoma: Polarization to type 1‐like differentiation pattern, clonal T‐cell expansion and tumor‐specific cytotoxicity , 1997, International journal of cancer.

[63]  B. Baban,et al.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. , 2005, Immunity.

[64]  J. Becker,et al.  In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. , 1999, Journal of immunology.

[65]  M. Claesson,et al.  Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck , 1995, Cancer Immunology, Immunotherapy.

[66]  W. Isaacs,et al.  Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+ , 2009, The Prostate.

[67]  J. Becker,et al.  The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase , 2009, PloS one.

[68]  F. Marincola,et al.  Expansion of Tumor-T Cell Pairs from Fine Needle Aspirates of Melanoma Metastases , 2000, The Journal of Immunology.

[69]  L. Steinman,et al.  Predominant expression of T cell receptor V alpha 7 in tumor-infiltrating lymphocytes of uveal melanoma. , 1990, Science.

[70]  I. Svane,et al.  Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. , 2011, Blood.

[71]  M. Gore,et al.  Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  J. Allison,et al.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.

[73]  R. Blasberg,et al.  Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts , 2010, The Journal of experimental medicine.

[74]  J. Becker,et al.  Comparative delineation of T cell clonotypes in coexisting syngeneic B16 melanoma , 2000, Cancer Immunology, Immunotherapy.

[75]  E. Segal,et al.  Minimally Cultured or Selected Autologous Tumor-infiltrating Lymphocytes After a Lympho-depleting Chemotherapy Regimen in Metastatic Melanoma Patients , 2009, Journal of immunotherapy.

[76]  I. Svane,et al.  Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. , 2011, Cancer research.

[77]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[78]  S. H. van der Burg,et al.  Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine , 2008, Clinical Cancer Research.

[79]  G. Zhu,et al.  Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. , 2007, Cancer research.

[80]  W. Dröge,et al.  Regulation of T-cell functions by L-lactate. , 1987, Cellular immunology.

[81]  S. Rosenberg,et al.  CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion , 2005, Cancer Immunology, Immunotherapy.

[82]  S. Rosenberg,et al.  Multiple HLA Class II-Restricted Melanocyte Differentiation Antigens Are Recognized by Tumor-Infiltrating Lymphocytes from a Patient with Melanoma , 2002, The Journal of Immunology.

[83]  F. Marincola,et al.  Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. , 1998, Journal of immunology.

[84]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[85]  C. von Buchwald,et al.  Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer. , 2011, Cytotherapy.

[86]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[87]  J. Becker,et al.  Activation of preexisting T cell clones by targeted interleukin 2 therapy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[88]  T. Schumacher,et al.  TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients , 2012, Oncoimmunology.

[89]  J. Becker,et al.  The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses. , 2004, The Journal of investigative dermatology.

[90]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[91]  Reduced Cytotoxic Function of Effector CD8+ T Cells Is Responsible for Indoleamine 2,3-Dioxygenase-Dependent Immune Suppression , 2009 .

[92]  S. Rosenberg,et al.  Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. , 1996, The cancer journal from Scientific American.

[93]  A. Akbar,et al.  Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo , 2006 .

[94]  J. Becker,et al.  Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. , 2001, Cancer research.

[95]  J. Becker,et al.  In situ T cells in melanoma , 1999, Cancer Immunology, Immunotherapy.

[96]  J. Becker,et al.  In situ cytokine therapy: redistribution of clonally expanded T cells , 2001, European Journal of Immunology.

[97]  H. von der Maase,et al.  Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  P. Coulie,et al.  Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells , 1992, International journal of cancer.

[99]  S. H. van der Burg,et al.  Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. , 2009, The New England journal of medicine.

[100]  B. Shalmon,et al.  Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients , 2010, Clinical Cancer Research.

[101]  R. Kiessling,et al.  Tumor‐induced changes in the phenotype of blood‐derived and tumor‐associated T cells of early stage breast cancer patients , 2012, International journal of cancer.

[102]  D. Keskin,et al.  Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase , 2002, Science.

[103]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[104]  G. D. de Bock,et al.  The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.

[105]  Jeffrey E. Lee,et al.  Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients , 2012, Clinical Cancer Research.

[106]  J. Becker,et al.  Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture. , 2000, Clinical immunology.

[107]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[108]  Polly Matzinger,et al.  Tissue-based class control: the other side of tolerance , 2011, Nature Reviews Immunology.

[109]  V. Bronte,et al.  Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.

[110]  Gregor Rothe,et al.  Inhibitory effect of tumor cell-derived lactic acid on human T cells. , 2007, Blood.

[111]  K. Sakaguchi,et al.  Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[112]  M. Donia,et al.  Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion. , 2013, The Journal of investigative dermatology.

[113]  P. Straten,et al.  Comment on “Reduced Cytotoxic Function of Effector CD8+ T Cells Is Responsible for Indoleamine 2,3-Dioxygenase-Dependent Immune Suppression” , 2009, The Journal of Immunology.

[114]  F. Garrido,et al.  HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank , 2009, Cancer Immunology, Immunotherapy.

[115]  D. Speiser,et al.  Tetramer-Guided Analysis of TCR β-Chain Usage Reveals a Large Repertoire of Melan-A-Specific CD8+ T Cells in Melanoma Patients1 , 2000, The Journal of Immunology.

[116]  A. Ghahary,et al.  High expression of IMPACT protein promotes resistance to indoleamine 2,3‐dioxygenase‐induced cell death , 2010, Journal of cellular physiology.

[117]  C. Ahonen,et al.  Tryptophan hydroxylase-1 regulates immune tolerance and inflammation , 2012, The Journal of experimental medicine.

[118]  Olga K Afanasiev,et al.  Merkel Cell Polyomavirus-Specific CD8+ and CD4+ T-cell Responses Identified in Merkel Cell Carcinomas and Blood , 2011, Clinical Cancer Research.

[119]  D. Munn,et al.  Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. , 2009, Blood.